Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors.
about
Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptorsDeveloping strategies in the immunotherapy of leukemiasEvaluation of current cancer immunotherapy: hemato-oncologyRecognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognitionIn Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid LeukemiaTargeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cellsIn Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid LeukemiaCo-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsCytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognitionCurative Effects of Dendritic Cells Combined with Cytokine-Induced Killer Cells in Patients with Malignant Pericardial Effusion.CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.Molecular therapeutic approaches for pediatric acute myeloid leukemia.New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future.Genetic engineering of T cells for the immunotherapy of haematological malignancies.Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.Update on antigen-specific immunotherapy of acute myeloid leukemia.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Cancer Immunotherapy with Cytokine-Induced Killer Cells.Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies.From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain.Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia.Engineering CAR-T cells.Highlights of the third International Conference on Immunotherapy in Pediatric Oncology.Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemiaTreatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT.CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
P2860
Q26795540-857B8ABA-806A-43A7-B964-60B77C704F6BQ26996310-DC0E0539-5C21-457D-B50D-2BD4DB448F81Q27006179-FF26536D-278E-4B51-88C3-DD8CCDD50670Q27311035-FA052330-DEC8-4CCF-8433-06DD9170571DQ28554677-A4D0600F-FEE2-404B-9551-30D9CC84A263Q34329186-37077891-8D74-4F6C-827D-CBC148DFCCFEQ34367252-0C999805-625B-4A9B-878E-B3DE28180D4BQ35146288-711DA28F-D292-4FA2-B0BA-ABB593EB8C57Q35591409-0E102356-DA7A-4DDE-A7B5-2A72C450C8BFQ35661999-F95D2800-2609-4209-9DF6-C31D121E0EF4Q35681332-7CA0258E-29DB-44D3-AE72-01453FD6C5BAQ36123941-E7BBB52E-DF67-4413-8D04-0F13B0B2C415Q36366557-F19606BF-63CD-490C-A3D5-E26E86DB581EQ36386891-0994A7C2-A022-4D10-A16B-169921751413Q36470354-19B507D1-777B-492F-8061-2C886A7EE7F9Q36544290-87AA23BD-7C71-4CD3-9407-A29FD02A2767Q37395436-FF103F3E-0E43-471E-956B-A973331B70D5Q37587956-06F3CA97-7B09-481B-9C96-9712F55FEAE1Q37588329-D88E989D-0C0B-4523-9150-6D2D59302478Q37643136-9713845E-F790-4EF4-8DC6-5CF5DE59EC54Q37937083-3DAF9C9C-DD76-4993-A8C7-F4E4DDAEE996Q37965815-3099FBD9-F080-4014-A2D2-33CA899FFEC7Q38219579-FCB0B802-3E2A-45A0-92F1-B01477713185Q38432103-0CE08DFD-FBBF-4731-8B09-23450E05B2F2Q38664735-2CBB519C-AD73-4FBF-AAC0-11D4AE1076DBQ38687547-E5270BDA-8C2F-44D7-9E69-1A38EF3AA8ECQ38700209-045A28BC-EB17-4800-A634-619CFE38661EQ38785870-C0A4C9DD-86B3-4F6B-88EE-6D0C51540A1EQ38787535-B7C9E3DF-F184-4C15-9798-2196960DDFF9Q38834059-DB009A51-5F31-4866-8B9E-32AA2261F11FQ38951943-3834A904-50BE-463C-8F5C-3D80F2BD15E6Q39026376-6FB1709C-15B3-4143-921A-23F9DAD26568Q39049730-A6AC5D0C-8C0B-4047-9529-BCCA8E617305Q39399864-F117878F-4922-47B6-9C9B-88EB20A6771DQ39403785-64B89B0F-2D37-488E-A186-ABD6D3326AA6Q39408105-59D176C6-17CB-42C4-9D55-9D463E9085CCQ41085306-0495BD3B-D7D9-4C49-8518-7BFF392FE3F3Q41558781-9331F9DE-65E7-439C-A1FB-29E86E8D1666Q41564670-4E04CD7F-73F9-42ED-92B9-32899EFC1B53Q41925285-CEFB9891-56F6-4D33-AE20-77E267B75BDA
P2860
Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Cytokine-induced killer cells ...... 3-specific chimeric receptors.
@en
Cytokine-induced killer cells ...... 3-specific chimeric receptors.
@nl
type
label
Cytokine-induced killer cells ...... 3-specific chimeric receptors.
@en
Cytokine-induced killer cells ...... 3-specific chimeric receptors.
@nl
prefLabel
Cytokine-induced killer cells ...... 3-specific chimeric receptors.
@en
Cytokine-induced killer cells ...... 3-specific chimeric receptors.
@nl
P2093
P2860
P1433
P1476
Cytokine-induced killer cells ...... 3-specific chimeric receptors.
@en
P2093
Alastair Lawson
Andrea Biondi
Ettore Biagi
Greta Maria Paola Giordano Attianese
Helene Finney
Irene Pizzitola
Martin Pule
Raphael Rousseau
Virna Marin
P2860
P304
P356
10.3324/HAEMATOL.2010.026310
P577
2010-08-16T00:00:00Z